Novocure Ltd
NASDAQ:NVCR
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.13
24.05
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NVCR stock under the Base Case scenario is 24.15 USD. Compared to the current market price of 16.59 USD, Novocure Ltd is Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Novocure Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NVCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Novocure Ltd
Balance Sheet Decomposition
Novocure Ltd
Current Assets | 1.1B |
Cash & Short-Term Investments | 959.9m |
Receivables | 92.5m |
Other Current Assets | 42.9m |
Non-Current Assets | 126.7m |
PP&E | 114.5m |
Other Non-Current Assets | 12.2m |
Current Liabilities | 735m |
Accounts Payable | 91.3m |
Short-Term Debt | 557.3m |
Other Current Liabilities | 86.4m |
Non-Current Liabilities | 126.2m |
Long-Term Debt | 97.1m |
Other Non-Current Liabilities | 29.1m |
Earnings Waterfall
Novocure Ltd
Revenue
|
577.7m
USD
|
Cost of Revenue
|
-136.2m
USD
|
Gross Profit
|
441.5m
USD
|
Operating Expenses
|
-598.4m
USD
|
Operating Income
|
-156.9m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
-149.8m
USD
|
Free Cash Flow Analysis
Novocure Ltd
USD | |
Free Cash Flow | USD |
NVCR Profitability Score
Profitability Due Diligence
Novocure Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Novocure Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
NVCR Solvency Score
Solvency Due Diligence
Novocure Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Novocure Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVCR Price Targets Summary
Novocure Ltd
According to Wall Street analysts, the average 1-year price target for NVCR is 28.56 USD with a low forecast of 18.18 USD and a high forecast of 42 USD.
Dividends
Current shareholder yield for NVCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NVCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Contact
IPO
Employees
Officers
The intrinsic value of one NVCR stock under the Base Case scenario is 24.15 USD.
Compared to the current market price of 16.59 USD, Novocure Ltd is Undervalued by 31%.